Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 5
2004 4
2005 2
2006 9
2007 9
2008 12
2009 12
2010 12
2011 17
2012 14
2013 17
2014 14
2015 9
2016 12
2017 15
2018 10
2019 9
2020 11
2021 9
2022 12
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Type 2 diabetes in adolescents and young adults.
Lascar N, Brown J, Pattison H, Barnett AH, Bailey CJ, Bellary S. Lascar N, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2018 Jan;6(1):69-80. doi: 10.1016/S2213-8587(17)30186-9. Epub 2017 Aug 25. Lancet Diabetes Endocrinol. 2018. PMID: 28847479 Review.
Exenatide.
Barnett AH. Barnett AH. Drugs Today (Barc). 2005 Sep;41(9):563-78. doi: 10.1358/dot.2005.41.9.893704. Drugs Today (Barc). 2005. PMID: 16341288 Review.
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators. Barnett AH, et al. Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. Lancet Diabetes Endocrinol. 2014. PMID: 24795251 Clinical Trial.
Insulin icodec: evolution or revolution in diabetes therapy?
Bellary S, Barnett AH. Bellary S, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2023 Jun;11(6):379-380. doi: 10.1016/S2213-8587(23)00125-0. Epub 2023 May 4. Lancet Diabetes Endocrinol. 2023. PMID: 37150185 No abstract available.
Empagliflozin for the treatment of type 2 diabetes.
Jahagirdar V, Barnett AH. Jahagirdar V, et al. Among authors: barnett ah. Expert Opin Pharmacother. 2014 Nov;15(16):2429-41. doi: 10.1517/14656566.2014.966078. Expert Opin Pharmacother. 2014. PMID: 25301180 Review.
Substance Use Terminology.
Barnett AI, Hall W, Carter A. Barnett AI, et al. JAMA. 2017 Feb 21;317(7):769-770. doi: 10.1001/jama.2016.20475. JAMA. 2017. PMID: 28241349 No abstract available.
Future glucose-lowering drugs for type 2 diabetes.
Bailey CJ, Tahrani AA, Barnett AH. Bailey CJ, et al. Among authors: barnett ah. Lancet Diabetes Endocrinol. 2016 Apr;4(4):350-9. doi: 10.1016/S2213-8587(15)00462-3. Epub 2016 Jan 23. Lancet Diabetes Endocrinol. 2016. PMID: 26809680 Review.
Pharmacotherapy for obesity in menopausal women.
Samat A, Rahim A, Barnett A. Samat A, et al. Among authors: barnett a. Menopause Int. 2008 Jun;14(2):57-62. doi: 10.1258/mi.2008.008005. Menopause Int. 2008. PMID: 18519266 Review.
209 results